# ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Study · id `cardio:ct-nct02319005` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02319005](<https://clinicaltrials.gov/study/NCT02319005>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02319005

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

## Technical summary

Registry record NCT02319005. Randomized; double masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2017-03-30 (actual). Results posted on 2018-07-18.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 206 participants (enrolled count; ClinicalTrials.gov record NCT02319005, source copy `cardio:ctgov-nct02319005-2018-07-18`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02319005, source copy `cardio:ctgov-nct02319005-2018-07-18`, retrieved 2026-10-26)
- Primary completion: 2017-03-30 (actual) (ClinicalTrials.gov record NCT02319005, source copy `cardio:ctgov-nct02319005-2018-07-18`, retrieved 2026-10-26)
- Completion: 2017-03-30 (actual) (ClinicalTrials.gov record NCT02319005, source copy `cardio:ctgov-nct02319005-2018-07-18`, retrieved 2026-10-26)
- Results first posted: 2018-07-18 (ClinicalTrials.gov record NCT02319005, source copy `cardio:ctgov-nct02319005-2018-07-18`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; France; Germany; Italy; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT02319005, source copy `cardio:ctgov-nct02319005-2018-07-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02319005-2018-07-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
- Condition: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
- Condition: Amyloidosis, Hereditary
- Condition: Amyloid Neuropathies, Familial
- Condition: Amyloid Neuropathies
- Condition: Amyloidosis, Hereditary, Transthyretin-Related
- Condition: Familial Transthyretin Cardiac Amyloidosis
- Intervention (Drug): Revusiran (ALN-TTRSC)
- Intervention (Drug): Sterile Normal Saline (0.9% NaCl)
- Lead sponsor: Alnylam Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Alnylam Pharmaceuticals (`cardio:org-alnylam-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) (`cardio:pubmed-32062791`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 83c8abb176d361e216c3cfa906f75f1ba42776fed44bfe6ee30f244f22417f44
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
